Several biological abnormalities in major depressive disorder (MDD) persist during episode remission, including altered serotonin neurotransmission, and may reflect underlying pathophysiology. We previously described elevated brain serotonin 1A (5-HT 1A ) receptor binding in antidepressant-naive (AN) subjects with MDD within a major depressive episode (MDE) compared with that in healthy controls using positron emission tomography (PET). In this study, we measured 5-HT 1A receptor binding in unmedicated subjects with MDD during sustained remission, hypothesizing higher binding compared with that in healthy controls, and binding comparable with currently depressed AN subjects, indicative of a biological trait. We compared 5-HT 1A binding potential (BP F ) assessed through PET scanning with [
INTRODUCTION
Biological abnormalities in major depressive disorder (MDD) that are trait phenomena may be more likely to be part of the etiology of MDD predisposing to recurrent episodes of major depression, in contrast to homeostatic mechanisms or stress responses occurring only during acute illness (Bhagwagar and Cowen, 2008) . There is evidence of trait serotonergic abnormalities in MDD. Acute tryptophan depletion provokes depressive symptoms in remitted depressed subjects and in their relatives, an effect not seen in healthy controls (Ruhe et al, 2007) . In addition, acute challenges with serotonergic agents, such as citalopram or fenfluramine, result in blunted neuroendocrine responses in remitted depressed subjects (Bhagwagar et al, 2002 , Flory et al, 1998 .
The 5-HT 1A receptor is located on the soma and proximal dendrites of serotonergic neurons in the brainstem raphe nuclei, in which it serves as an auto-receptor, and postsynaptically in the cortex and terminal fields (Aghajanian and Sanders-Bush 2002) . We have previously reported that during a major depressive episode (MDE), antidepressantnaive (AN) MDD subjects have higher 5-HT 1A receptor binding in vivo than healthy controls as assessed by positron emission tomography (PET; outcome measure binding potential (BP F ) ¼ B avail /K D where B avail is the receptor density available for binding and 1/K D is the affinity of radioligand) (Parsey et al, 2006d) . This is consistent with reports of elevated 5-HT 1A brain receptors in animal models of depression, including 5-HT 1A elevations in mice bred for helplessness on the tail suspension test (Naudon et al, 2002) , and hippocampal 5-HT 1A elevations among behaviorally depressed cynomolgus macaques in a postmortem quantitative receptor autoradiography study (Shively et al, 2007) , although a PET imaging study by this group using the outcome measure BP P showed discrepant findings (Shively et al, 2006) . Studies of neuroendocrine responses to 5-HT 1A receptor agonists in MDD have been inconsistent (reviewed in Navines et al (2007) . There are also discrepancies in PET imaging findings regarding 5-HT 1A abnormalities in MDD (Drevets et al, 1999 (Drevets et al, , 2007 Hirvonen et al, 2008; Meltzer et al, 2004; Moses-Kolko et al, 2007b; Sargent et al, 2000) ; divergent findings may be partly related to methodological differences and patient samples (see the Discussion section for further details). Postmortem studies of 5-HT 1A receptor binding in depression and/or suicide have variously reported increases, no changes, or decreases (reviewed in Stockmeier (2003) ; see also Boldrini et al (2008) ). To our knowledge, no postmortem study has examined 5-HT 1A receptor binding among subjects with remitted depression.
A previous PET study found persistent 5-HT 1A receptor abnormalities during remission from MDD among 14 male subjects compared with 18 controls using the outcome measure BP ND (Bhagwagar et al, 2004) . In this study, we assessed 5-HT 1A binding among 15 remitted depressed subjects using cerebellar white matter as the reference region to estimate the outcome measure BP F . On the basis of our findings among currently depressed subjects, we hypothesized that 5-HT 1A BP F would be higher in those with recurrent MDD in sustained remission compared with that in healthy controls, consistent with a trait abnormality. As a secondary aim, we hypothesized that 5-HT 1A BP F would not differ significantly between subjects with MDD in sustained remission and AN subjects with MDD in a current MDE.
In an exploratory manner, we genotyped subjects for a functional C-1019G promoter polymorphism of the 5-HT 1A gene (Lemonde et al, 2003) . The G allele has been associated with greater expression in raphe neuron cell cultures in vitro (Lemonde et al, 2003) , with greater raphe nucleus binding in vivo (Parsey et al, 2006d) , with the diagnosis of MDD, and with diminished response to antidepressant treatment (Le François et al (2008) . Therefore, although this study was underpowered for genetic analyses, we explored the hypothesis that the G allele would be less frequent among remitted MDD subjects compared with current MDD subjects, among whom only a portion will eventually achieve remission.
MATERIALS AND METHODS

Subjects
Fifteen subjects who met criteria for MDD in full remission, 51 healthy controls, and 13 AN currently depressed subjects with MDD were included in this study. This study draws on PET data from 42 healthy controls and 13 AN currently depressed MDD patients from a previous study (Parsey et al, 2006d) ; those subjects underwent PET scanning between 29 July 1999 and 25 March 2003. In this study, 15 subjects with MDD in full remission and a second cohort of 9 healthy controls underwent PET scanning with 2007. Clinical assessments, PET acquisition, reconstruction, and image processing did not differ between groups. There was no evidence of drift in PET camera performance over the study period based on quality control measurements, including cross-calibration factor (in this assay, which is performed bimonthly, the HR + scanner is calibrated using a cylindrical phantom filled with 18 F. The phantom is scanned using the HR + for 30 min. Ten samples of the activity (2 ml each) are taken from the phantom and measured in a Wallac 1480 Wizard well counter (PerkinElmer Lifescience). The cross-calibration factor is the ratio of detected counts between the scanner and the well counter). After a comparison of first and second cohorts of healthy controls showed no differences in 5-HT 1A BP F considering all regions of interest (ROIs) (F ¼ 0.38, df ¼ 1.49, p ¼ 0.54), these cohorts were combined in subsequent analyses. Subjects were recruited through community advertisements; remitted depressed subjects were already in remission at the time of recruitment. Eligibility was assessed by psychiatric and medical history, chart review, SCID, (Structured Clinical Interview for DSM-IV) (First et al, 1995) , physical examination, routine blood tests, pregnancy test, and urine toxicology. The Beck Depression Inventory (BDI) (Beck et al, 1961) , Hamilton Depression Rating Scale (HAM-D) (Hamilton, 1960) , GAS (Global Assessment Scale) (Endicott et al, 1976) , and Beck Hopelessness Scale (Beck et al, 1974) , assessed depression severity and functional impairment.
Inclusion criteria for remitted depressed subjects were (1) DSM-IV criteria for MDD, in full remission for at least 1 year; (2) X2 previous MDEs; (3) 17-item HAM-D o8 on screening; (4) absence of psychotropic medication use for X6 months before the PET scan (to minimize the effects of previous antidepressant treatment on 5-HT 1A BP F (Parsey et al, 2006d; Spindelegger et al, 2008) ); (5) age 18-65 years; (6) no current or lifetime history of alcohol or other drug abuse or dependence; (7) absence of lifetime exposure to 3,4-methylenedioxymethamphetamine; (8) absence of significant current medical conditions; (9) absence of pregnancy; and (10) capacity to provide informed consent. We required a minimum of two previous MDEs, given findings of greater biological abnormalities in recurrent as opposed to single-episode MDD (Basso and Bornstein, 1999; Kupfer et al, 1991; Thase, 1992; Thase et al, 1995) , with at least one difference persisting into remission (Jindal et al, 2002) . Healthy controls met inclusion criteria (5)-(10), had no psychiatric history, and had no history of a mood or psychotic disorder in their first-degree relatives. AN subjects with current MDD met DSM-IV criteria for a current MDE and had never taken antidepressant medication; these subjects met inclusion criteria (5)-(10) mentioned above. Comorbid disorders among remitted depressed subjects, which were in remission, included post-traumatic stress disorder (n ¼ 1) and attention-deficit hyperactivity disorder (n ¼ 1). Among AN currently depressed subjects, comorbid disorders included panic disorder (n ¼ 4), post-traumatic stress disorder (n ¼ 2), dysthymia (n ¼ 3), and social anxiety disorder (n ¼ 1). This study was approved by the Institutional Review Board of the New York State Psychiatric Institute. All subjects gave written informed consent after explanation of the study.
Radiochemistry
[
11 C]WAY-100635 was prepared as previously described . (Parsey et al, 2005b) . [
11 C]WAY-100635 equilibrium distribution volume (V T ) should be insensitive to changes in injected mass if the receptor occupancy is below 10% (Slifstein and Laruelle, 2001 ). Indeed, there was no significant correlation between injected mass or dose and V T in any ROI (representative pre-and post-synaptic regions: raphe nucleus and injected mass: r ¼ 0.075, p ¼ 0.51; raphe nucleus and injected dose: r ¼ 0.025, p ¼ 0.82; hippocampus and injected mass: r ¼ 0.14, p ¼ 0.20; hippocampus and injected dose: r ¼ 0.11, p ¼ 0.36).
Measurement of the arterial input function, plasma-free fraction (f P ), and metabolites was conducted as described previously . f P was lower among remitted depressed than controls, but did not differ between remitted depressed and AN currently depressed subjects (remitted
PET and MRI Acquisition
After placement of an arterial and venous catheter, PET imaging was performed on an ECAT EXACT HR + (Siemens/CTI, Knoxville, TN) (63 slices covering an axial field of view of 15.5 cm, axial sampling of 2.46 mm, in a three-dimensional (3D) mode. A 10-min transmission scan was acquired before injection of [ 11 C]WAY-100635 as an intravenous bolus over 45 s. Emission data were collected for 110 min as 20 successive frames of increasing duration. Images were reconstructed using the 3D-RP algorithm implemented on a vector processor (CTI) to a 128 Â 128 matrix (pixel size of 1.7 Â 1.7 mm 2 ) with attenuation correction and a Shepp 0.5 filter (cutoff 0.5 cycles/ projection rays) resulting in an in-plane and axial resolution (ie, full-width half-maximum) of 4.4 and 4.1 mm in air and at the center of the field of view (Brix et al, 1997) . Scatter correction was performed using the technique implemented by the manufacturer (Watson et al, 1995) .
Acquisition of T 1 -weighted MRI for co-registration of PET images and identification of ROIs was performed as previously described using a 1.5 T Signa Advantage or a 3 T Signa HDx system (General Electric Medical Systems, Milwaukee, WI) .
Image Analysis
Image analysis was performed using MATLAB 2006b (The Mathworks, Natick, MA) with extensions to the following open source packages: Functional Magnetic Resonance Imaging of the Brain's Linear Image Registration Tool (FLIRT) v5. (Jenkinson and Smith, 2001 ), Brain Extraction Tool (BET) v1.2 (Smith, 2002) , as well as Statistical Parametric Mapping (SPM5) normalization (Ashburner and Friston, 1999) and segmentation routines (Ashburner and Friston, 2005) . No attempt was made to correct for transmission-emission mismatch. To correct for subject motion, de-noising filter techniques were applied to all PET images starting at frame five. The eighth frame was used as a reference to which all other frames were aligned using rigid body FLIRT. Motion correction was assessed visually by comparing movies of pre-and post-motion correction scans. Motion was evaluated for drift between frames and across the entire scan duration, separately. A mean of motion corrected frames 8-18 for each subject was registered to that subject's T 1 -weighted MRI using FLIRT.
ROIs were hand drawn on individual subjects' T 1 -weighted MRI images by experienced technicians trained to reliably approximate these regions using brain atlases (Duvernoy, 1991; Talairach and Tournoux, 1988) and published reports (Kates et al, 1997; Killiany et al, 1997) . ROIs included the ventral prefrontal cortex (PFC), medial PFC, dorsolateral PFC, anterior cingulate, body of the cingulate (posterior to anterior cingulate), amygdala, hippocampus, parahippocampal gyrus, insular cortex, temporal cortex, parietal cortex, and occipital cortex. A fixed volume elliptical ROI (2 cm 3 ) was placed on the raphe nuclei in the dorsal midbrain; a composite of mostly the dorsal and median raphe nuclei on a mean PET image for each subject as the boundaries of this structure cannot be identified on MRI. A cylindrical ROI was drawn in the cerebellar white matter, which was used as the reference region for this study, as it has been previously shown to have the lowest concentration of 5-HT 1A receptors within the cerebellum, and is adequately modeled by a one-tissue compartment model (Parsey et al, 2005a) . For comparison purposes, a cylindrical ROI was drawn in the cerebellar gray matter. The segmented MRI image was used to refine the contours of the ROI to more accurately reflect the gyral pattern and differences between the PET and MRI fields of view.
Quantitative Analysis
Regional distribution volumes of [ 11 C]WAY-100635 were derived from kinetic analysis using the arterial input function and a two-tissue compartment (2T) model as the general framework (for details see Parsey et al, 2000) . V ND and V S are defined as the distribution volumes of the non-displaceable and specific compartments, respectively (Laruelle et al, 1994; Mintun et al, 1984) . V T , the total regional equilibrium distribution volume, is equal to V ND + V S . The primary outcome measure for this study was binding potential (BP F ¼ B avail /K D ). Time-activity curves were fit with a 2T model, which has the K 1 /k 2 ratio fixed to that of the cerebellar white matter (reference region). BP F was calculated as (V T(ROI) ÀV T(CER) )/f P or (V T ÀV ND )/f P . For comparison purposes, the outcome measure, BP ND , was calculated using the simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996) using both the cerebellar white and gray matter, as was the outcome
The contribution of plasma total activity to regional activity was calculated assuming a 5% blood volume in the ROI and was subtracted before analysis. Kinetic parameters were derived by nonlinear regression using the Levenberg-Marquart least squares minimization procedure implemented in MATLAB (The Math Works Inc., South Natick, MA).
Genotyping
Genotyping of the C(-1019)G polymorphism of the 5-HT 1A receptor gene was performed using allele-specific PCR amplification as previously described (Parsey et al, 2006d) .
Statistical Analysis
To properly account for correlations among measurements made on the same subject, we applied mixed-effects modeling methods and analyzed the data for the 13 regions simultaneously, with region and diagnostic group as fixed effects and subject as the random effect. SEs were computed for each estimated BP F value using a bootstrap algorithm that takes into account errors in the metabolite, plasma, and brain data (Ogden and Tarpey, 2006) . Observations were weighed accordingly in the linear mixed-effects models to increase precision in group estimates. Analyses were performed on natural log-transformed values. Log transformation is commonly used to remedy problems with skewness and unequal variance, both of which are generally issues with PET data. It has specifically been used in previous PET studies by our group and others to address these issues (Hirvonen et al, 2008; Miller et al, 2008; Oquendo et al, 2007; Parsey et al, 2006a, b, c, d; Sullivan et al, 2005) . Other groups have used related statistical approaches, including linearizing transformation (Rabiner et al, 2002b) and non-parametric testing (Meltzer et al, 2004) to address these issues in analyzing PET data. As the natural log is a monotone transformation, demonstrating a difference in log(BP F ) is equivalent to demonstrating a difference (in the same direction) in BP F . Figure 1 presents raw BP F values. Reported p-values were not adjusted for multiple comparisons. Linear mixed-effects models of binding and Fisher's exact tests were performed in R 2.1.0 (http://www.cran.r-project.org). t-tests were performed in Excel (Microsoft, 2003) .
RESULTS
Clinical Characteristics
Clinical characteristics of the study sample are presented in Table 1 . The remitted MDD group had depression severity ratings that were modestly greater than those of the healthy volunteers and only 10% that of the acutely depressed MDD group for the BDI. Both MDD groups had a comparable number of previous MDEs; the remitted group had been free from an episode for a mean of 3 years at the time of study participation. About 60% of both MDD groups had a first-degree relative with MDD. Clinical assessments reported in this study were obtained within an average of 3.7±5.2 days of PET scanning.
Comparison of 5-HT 1A BP F Between Groups
Remitted depressed subjects had higher 5-HT 1A BP F compared with healthy controls, including all brain regions in the model (Figure 1 ; F ¼ 4.99, df ¼ 1.90, p ¼ 0.028). As we have found an inverse relationship between aggression (BrownGoodwin Aggression scale) and 5-HT 1A BP F , as well as a sex effect, with higher 5-HT 1A BP F among women (Parsey et al, 2002) , sex and aggression scores were included as covariates in linear mixed-effects models. The difference between remitted depressed subjects and healthy controls remained statistically significant with inclusion of sex and aggression as covariates in the model (F ¼ 8.45, df ¼ 1.86, p ¼ 0.0046). The magnitude of difference between these groups did not vary across the brain regions examined (region-by-diagnosis interaction: F ¼ 1.36, df ¼ 12.756, p ¼ 0.18).
5-HT 1A BP F did not differ between remitted MDD and AN acutely depressed MDD subjects (Figure 1; F 
Alternative Outcome Measures
To compare our findings with other studies, we repeated the primary analysis comparing remitted depressed subjects with healthy controls using the outcome measure BP ND , estimated by the simplified reference tissue method , consistent with methods used in a previous publication examining 5-HT 1A binding in remitted depression (Bhagwagar et al, 2004) . We performed this comparison using two different reference regions, cerebellar white matter and cerebellar gray matter. When using the cerebellar white matter as the reference region, BP ND was an average of 11.4% higher across all ROIs among remitted depressed subjects than controls, although this difference was not statistically significant (F ¼ 1.66, df ¼ 1.61, p ¼ 0.20). In contrast, when the cerebellar gray matter was used as the reference region, which has appreciable 5-HT 1A binding (Parsey et al, 2005a) , BP ND was an average of 22.6% lower across all ROIs among remitted depressed subjects than controls (F ¼ 10.78, df ¼ 1.61, p ¼ 0.002). Although the V T of the reference region used for our primary analyses, the cerebellar white matter, did not differ significantly between remitted depressed and control subjects (remitted depressed: 0.25 ± 0.10, controls: 0.29 ± 0.11, t ¼ 1.16, df ¼ 64, p ¼ 0.25), there was a trend toward higher V T in the alternative reference region of cerebellar gray matter among remitted depressed subjects compared with controls (remitted depressed: 0.57 ± 0.25, controls: 0.47 ± 0.19, t ¼ 1.71, df ¼ 64, p ¼ 0.092).
When we re-analyzed our data using the outcome measure BP P ( ¼ V T ÀV ND ¼ f p B avail /K D ), which requires the assumption of equivalent f P between groups, but which therefore does not require f P measurement, using cerebellar white matter as the reference region, differences in 5-HT 1A BP P between remitted depressed subjects and controls were not statistically significant (F ¼ 0.38, df ¼ 1.64, p ¼ 0.54).
5-HT 1A Receptor Promoter Polymorphism
For genetic analysis, we included antidepressant exposed with antidepressant-naive currently depressed subjects from the currently depressed MDD cohort (described in Parsey et al, 2006d) , as previous medication status does not affect genotype, comparing these 28 currently depressed subjects with remitted depressed subjects and healthy volunteers for the C(-1019)G polymorphism in the 5-HT 1A receptor gene. Considering all three groups simultaneously (healthy controls, remitted MDD, and currently depressed MDD), there was a difference in genotype between groups, with higher frequency of the GG genotype in the MDD groups (Table 2; Fisher's exact test, p ¼ 0.019). In pair-wise group comparisons of genotype frequency, the only two groups that differed significantly in genotype were currently depressed and control groups (Fisher's exact test, p ¼ 0.005); there were not significant differences between controls and remitted depressed (Fisher's exact, p ¼ 0.54) or between remitted depressed and currently depressed groups (Fisher's exact, p ¼ 0.23). The G allele was similarly more frequent in the current MDD group than in the control group (Fisher's exact, p ¼ 0.038).
DISCUSSION
We find higher 5-HT 1A BP F across all studied brain regions in subjects with recurrent MDD in sustained remission and who were off antidepressant medications for at least 6 months compared with that in healthy controls. In addition, we do not find a significant difference in 5-HT 1A BP F between remitted and currently depressed MDD subjects. These findings are consistent with a trait abnormality in 5-HT 1A receptor BP F in MDD.
Although the current findings may appear at odds with a report of lower 5-HT 1A BP ND among remitted depressed subjects compared with controls (Bhagwagar et al, 2004) , that study used the entire cerebellum as the reference region, and estimated the outcome measure BP ND . Inclusion of the cerebellar vermis and gray matter in a reference region may lead to bias in resulting binding estimates, given the detectable 5-HT 1A binding in these subregions (Parsey et al, 2005a) . Small differences in the reference region distribution volume (V ND ) can have large effects on BP ND , as BP ND is equal to (V T ÀV ND )/V ND , and V ND is typically o1. When we re-analyzed our data using the cerebellar gray matter as the reference region, estimating BP ND using SRTM, BP ND was an average of 22.6% lower across all ROIs among remitted depressed subjects than controls, consistent with the findings of Bhagwagar et al (2004) . In contrast, when BP ND was estimated using the cerebellar white matter as the reference region, mean BP ND was 11.4% higher across all ROIs among remitted depressed subjects than controls, although this difference was not statistically significant. This difference was driven by a trend toward higher V T in the alternative reference region of cerebellar gray matter among remitted depressed subjects compared with controls, consistent with our reports of appreciable 5-HT 1A receptor (Parsey et al, 2005a) . This result reconciles seemingly disparate findings, and emphasizes the importance of considering specific methodology, including the reference region and outcome measure used, in interpreting PET findings . We used BP F as the outcome measure in this study as it is the closest measure to B avail among the existing outcome measures for PET studies (BP F , BP P , and BP ND ). However, estimating BP F requires measurement of f P , which is particularly low with [ 11 C]WAY-100635. When we reanalyzed our data using the outcome measure BP P
, which requires the assumption of equivalent f P between groups, but which therefore does not require f P measurement, 5-HT 1A BP P was numerically higher among remitted depressed subjects than controls (an average of 9.2% higher across all ROIs), although this difference was not statistically significant. This suggests that the observed difference in BP F between groups is partially dependent on f P . We observed lower f P among remitted depressed subjects than controls; we had previously found non-significantly lower f P among currently depressed subjects than controls (Parsey et al, 2006d) . If such a peripheral marker was found to reliably correlate (inversely) with cerebral 5-HT 1A BP F , it could be used clinically as a less invasive surrogate marker for cerebral 5-HT 1A binding. However, there is a significant overlap in [ 11 C]WAY-100635 f P between groups, and f P is insensitive to regional heterogeneity in brain receptor binding. Of note, Hirvonen et al (2008) previously compared AN currently depressed subjects with healthy controls using the outcome measure BP P , reporting lower 5-HT 1A BP P among currently depressed subjects than controls; that study did not examine remitted depressed subjects. Differences in methodology include their use of atlas-based methods for automated ROI labeling. In addition, it is possible that frequencies of the C-1019G 5-HT 1A receptor polymorphism Beck depression inventory 1.6 ± 2.5 2.6 ± 2.9 26.9 ± 8.1 0.19 o0.0001
Global assessment scale 90.1±4.6 86.3±7.5 52.5±12.8 0.02 o0.0001
Beck hopelessness scale 1.7 ± 2.3 2.5 ± 2.4 9.6 ± 6.1 0.21 0.0003
Brown-Goodwin aggression scale 13.6 ± 4.1 18. ± 4. 
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Race 0 (0) 1 (6.7) 1 (7.7) a p-value associated with non-parametric Mann-Whitney test as some subjects reported 'too numerous to count' before depressive episodes. One control and one remitted MDD subject were not genotyped. JM Miller et al differed between samples, although this was not reported in their study, which may also have contributed to discrepant findings in comparing currently depressed subjects with controls. Our findings are consistent with broadly distributed elevations in 5-HT 1A receptor binding as a trait abnormality in MDD. On the basis of these results, we propose the following model to integrate several recent findings by our group and others regarding longitudinal 5-HT 1A expression in major depression (Figure 2) . Due to genetics, childhood experiences, or gene-environment interactions, AN subjects with MDD have higher 5-HT 1A BP F than healthy controls by the time of the onset of a first MDE. If this receptor difference is important causally, one would predict that 5-HT 1A receptor differences precede the development of depressive symptomatology, a question for future study. Chronic treatment with antidepressants may then lead to reductions in 5-HT 1A BP F , although data are inconclusive. We find lower 5-HT 1A BP F among MDD subjects who have received previous antidepressant treatment compared with medication-naive MDD subjects, providing cross-sectional evidence of medication effects (Parsey et al, 2006d) . A reduction in 5-HT 1A BP ND after X12 weeks of treatment with escitalopram was reported in subjects with social phobia or panic disorder, indicating receptor downregulation with chronic SSRI use (Spindelegger et al, 2008) . Consistent with these human findings, mice that have been stressed by housing in isolation show increased 5-HT 1A receptor binding, which is reversed postsynaptically by chronic treatment with the SSRI citalopram (Gunther et al, 2008) . In contrast, other human studies have not observed changes in 5-HT 1A binding after shorter SSRI courses in major depression (MosesKolko et al, 2007a , Sargent et al, 2000 . Finally, we find higher 5-HT 1A BP F in remitted depressed subjects who were off antidepressant medications for a minimum of 6 months compared with controls, suggesting that 5-HT 1A BP F increases again over time after stopping antidepressant medication, returning to elevated pre-treatment levels without return of MDE, and that it remains persistently elevated into remission among subjects not taking antidepressant medication.
5-HT 1A Receptor Binding in Remitted Depression
Trait elevations in 5-HT 1A BP F in MDD could be partly explained by a genetic model of overrepresentation of the G allele of the 5-HT 1A C(-1019)G polymorphism among subjects with MDD (Albert, 2004) . This would lead to higher 5-HT 1A auto-receptor binding in the raphe nucleus (Parsey et al, 2006d) , leading to greater inhibition of serotonergic neuronal firing and decreased serotonin release in the terminal field of serotonin neurons, potentially leading to compensatory upregulation of 5-HT 1A receptors in the terminal field. Whether less serotonin release related to this polymorphism would result in post-synaptic 5-HT 1A receptor upregulation to compensate for serotonergic deficit is not known (Cahir et al, 2007) , although a neurodevelopmental model would be required to test this hypothesis thoroughly.
This genetic model is limited, as we did not observe an association between C(-1019)G polymorphism and 5-HT 1A binding among the modest sample of remitted depressed subjects in this study (F ¼ 1.34, df ¼ 2.9, p ¼ 0.31) although such an association was previously observed when considering a larger sample of 42 healthy controls and 28 currently depressed MDD subjects (Parsey et al, 2006d) . In addition, many subjects who develop MDD do not carry the G allele of this polymorphism, and differences in genotype frequency were only significant comparing currently depressed subjects with controls. The fact that allelic frequencies at this locus for remitted depressed subjects were intermediate between healthy controls and currently depressed subjects, but not significantly different from either group, may simply be due to the small size of this sample for genetic studies. Alternatively, although speculative, it is possible that subjects with MDD who achieve sustained remission have a lower frequency of the G allele compared with other MDD subjects (Le François et al, 2008) , predisposing them to a better antidepressant response and to a greater likelihood of sustained remission. Larger sample sizes are clearly needed to test this hypothesis thoroughly.
Although we did not observe region-by-diagnosis interactions when comparing remitted depressed subjects with either controls or AN currently depressed subjects, there are some regions in which remitted depressed 5-HT 1A BP F appears closer to controls than to AN currently depressed subjects (Figure 1 ). This suggests the need for replication studies with larger sample sizes to study whether 5-HT 1A BP F may normalize partially in a regionally specific manner during sustained remission from MDD. There were some clinical and demographic differences between groups. Lifetime aggression (which has been associated with 5-HT 1A BP F ) was higher among remitted depressed subjects than controls. Differences in 5-HT 1A BP F between remitted depressed and controls remained highly significant after aggression was included as a co-variate. The remitted depressed group had a higher proportion of Caucasian individuals than controls or AN currently depressed subjects, and was more highly educated than the AN currently depressed group. There was also a trend toward a lower unemployment rate among remitted depressed than AN currently depressed subjects (13 vs 50%, p ¼ 0.08). These factors were all associated with a higher likelihood of remission with citalopram treatment in the STAR*D trial (Trivedi et al, 2006) , consistent with the frequencies observed in our sample. Although we are unaware of any studies reporting differences in 5-HT 1A binding as a function of race or ethnicity, group differences in ethnicity may have affected allelic frequencies of the 5-HT 1A receptor promoter polymorphism examined. Although not statistically significant, remitted depressed subjects were 6 years younger than healthy controls on average. We and others have previously found no effect of age on 5-HT 1A binding (Parsey et al, 2002; Rabiner et al, 2002a; Sargent et al, 2000) . Similarly, we found no correlation between age and 5-HT 1A BP F in any region in the current cohort. Although others have described agerelated decline in 5-HT 1A binding (Bhagwagar et al, 2004; Cidis Meltzer et al, 2001; Moller et al, 2007; Tauscher et al, 2001) , the magnitude of these reported effects is insufficient to explain our findings, given the small difference in age between groups. There was a higher incidence of comorbid anxiety disorders among AN currently depressed subjects compared with remitted depressed subjects. Although panic disorder and social anxiety disorder have been associated with lower 5-HT 1A receptor binding (Lanzenberger et al, 2007; Nash et al, 2008; Neumeister et al, 2004) , the small number of subjects with these comorbidities in the current sample prevented statistical analysis of such effects.
This study has some limitations. It has a modest sample size of remitted depressed subjects. In addition, remitted depressed subjects reported past antidepressant exposure, but this exposure was on average 3 years earlier, and hence is unlikely to have had persistent effects on 5-HT 1A BP F . Any residual effects of past antidepressant medication on 5-HT 1A receptors among remitted depressed subjects would be expected to lead to lower 5-HT 1A BP F (Parsey et al, 2006d) , and thereby to an underestimation of the magnitude of the difference we report between remitted depressed subjects and healthy controls. Remitted depressed subjects were recruited once they were already in sustained remission; their clinical history was therefore based on subjects' retrospective reports of previous depressive episodes and symptoms. Future studies could identify subjects prospectively by following-up individuals assessed during a current MDE into periods of sustained remission. Finally, PET data from some healthy controls and all AN depressed subjects in comparator groups were collected from a previous study (Parsey et al, 2006d) . This is unlikely to have influenced the results reported in this study, as PET acquisition, processing, and data analysis did not differ between groups. There was no difference in 5-HT 1A BP F between the first and second cohorts of controls, making temporal drift an unlikely explanation of our findings. Although T 1 -weighted MRIs used for identification of ROIs were performed on 1.5 and 3 T cameras, we observed no difference in the volume of a representative ROI, the dorsolateral PFC, as a function of MRI camera (comparison among remitted depressed: t ¼ 0.90, df ¼ 13, p ¼ 0.38; comparison among healthy controls: t ¼ 1.08, df ¼ 49, p ¼ 0.29). Similarly, regional [
11 C]WAY-100635 V T values did not differ as a function of MRI camera when comparing age-and sex-matched controls considering all ROIs (F ¼ 0.004, df ¼ 1,11.87, p ¼ 0.95).
5-HT 1A BP F may serve as a biological marker in populations at risk for the development of MDD (including those with a family history of mood disorder), which could be used for the purposes of screening and primary prevention. Future studies should examine genetic and non-genetic causes of elevated 5-HT 1A receptor BF F in MDD, its relationship to treatment outcome, and the effect of treatment on binding.
In summary, this study provides evidence of persistently elevated 5-HT 1A receptor BP F among subjects with MDD in sustained remission, consistent with a trait serotonergic abnormality in MDD. Apparent discrepancies between this finding and previously published findings are reconciled through a close analysis of PET acquisition and analysis methodologies.
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